PRODUCTION OF HUMAN BLOOD PLASMA-DERIVED BLOOD COAGULATION FACTOR XIII

摘要

PURPOSE:To obtain a human blood plasma-derived blood coagulation factor XIII in which contaminated pathogenic viruses are completely inactivated with a high residual activity ratio, by heat-treating a purified human blood coagulation factor XIII in a liquid form in the presence of albumin. CONSTITUTION:A solution containing a human blood plasma-derived blood coagulation factor XIII (hereinafter referred to as factor XIII), such as blood plasma, cryoprecipitates or fraction I paste obtained by the Cohn fractionation method, is treated with glycine and sodium chloride in respective final concentrations of 1.0-2.0 M under conditions of 10-25 deg.C and pH 6.0-7.0 to provide the high-purity factor XIII as precipitates in high yield. The purified factor XIII fraction is then dissolved and heat-treated at 50-80 deg.C temperature in the presence of 0.1-10wt./vol.% albumin for 3-18hr to afford the aimed factor XIII in which contaminated viruses are inactivated.